Using comprehensive indicators, our study showed that early intensive insulin treatment could not only reduce waist circumference, blood pressure, blood glucose (FPG, 2-h postprandial PG, HbA1c concentration, AUCGlu during both IVGTT and OGTT), blood lipid levels (TG, TC, and LDL-C), levels of traditional inflammatory factors (WBC and FFA), and insulin resistance (HOMA-IR), but also distinctly improve the HDL-C levels, insulin sensitivity (IAI, QUICKI, and ISIced) and β-cell function (HOMA-β, MBCI, AIR3–5, ∆Ins30/∆G30, and AUCIns during IVGTT and OGTT) in patients with newly diagnosed T2DM. The gene discussed is INS; the disease is Insulin resistance.